Maxim Group Maintains Buy on Palisade Bio, Adjusts Price Target To $22.5 (reverse stock split 1:15)
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Naz Rahman has maintained a Buy rating on Palisade Bio (NASDAQ:PALI) and adjusted the price target to $22.5, following a 1:15 reverse stock split.
April 16, 2024 | 5:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Maxim Group maintains a Buy rating on Palisade Bio with an adjusted price target of $22.5 post a 1:15 reverse stock split.
The maintenance of a Buy rating and the adjustment of the price target post-reverse stock split indicate a positive outlook from Maxim Group towards Palisade Bio. This could signal confidence in the company's future performance and potentially lead to increased investor interest, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100